Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

52.73 +2.21 (+4.38%)
Streaming Delayed Price Updated: 3:12 PM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Moderna Inc (NASDAQ:MRNA) Beats Q4 2025 Estimates Amid Post-Pandemic Transition ↗
Via Chartmill
News headline image
Moderna (NASDAQ:MRNA) Exceeds Q4 CY2025 Expectations
Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its GAAP loss of $2.11 per share was 18.9% above... 
Via StockStory
Topics Artificial Intelligence
News headline image
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
Via ACCESS Newswire
News headline image
Nasdaq, S&P 500 Futures Edge Lower Ahead Of CPI Data: Why NVDA, AAPL, TSLA, RIVN, MRNA, AMAT, IREN Are On Traders' Radar Today ↗
Data on Stocktwits showed retail traders remained bearish on SPY and ‘extremely bearish’ on QQQ. 
Via Stocktwits
Topics Bonds ETFs Economy
News headline image
Moderna: Stock to Avoid or Bad News Buy? ↗
Moderna stock was a highflier in early pandemic days as sales of its coronavirus vaccine soared. 
Via The Motley Fool
News headline image
FDA Stuns Moderna with Refusal to Review Flu Vaccine, Sending Shares Tumbling 3.5%
Shares of Moderna, Inc. (NASDAQ: MRNA) fell 3.5% on February 12, 2026, as investors continued to digest the fallout from a rare and unexpected regulatory setback. The U.S. Food and Drug Administration... 
Via MarketMinute
Topics Earnings
News headline image
The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation
The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of... 
Via Finterra
Topics Initial Public Offering Intellectual Property
AI Agents and the Jobs Report Jitter: A Wall Street Balancing Act ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
What To Expect From Moderna’s (MRNA) Q4 Earnings
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday before market hours. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
Gapping S&P500 stocks in Wednesday's session ↗
Via Chartmill
News headline image
Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology
Today, February 11, 2026, marks a volatile chapter for Moderna, Inc. (NASDAQ: MRNA). The biotechnology pioneer, which became a household name during the COVID-19 pandemic, finds itself at a critical... 
Via Finterra
Topics Artificial Intelligence Initial Public Offering Intellectual Property
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Rise Ahead Of Delayed Jobs Data: Why NVDA, WBD, HOOD, MRNA, ASTS Are On Traders' Radar Today ↗
Retail chatter on Stocktwits shows that sentiment remains deeply bearish on SPY and QQQ. 
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
News headline image
Why Did Moderna Stock Tumble Nearly 10% After Hours Today? ↗
The FDA’s CBER issued a refusal-to-file letter for Moderna’s flu vaccine mRNA-1010. 
Via Stocktwits
News headline image
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Via ACCESS Newswire
News headline image
1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell ↗
Vertex stock has climbed more than 60% over three years. 
Via The Motley Fool
Topics Intellectual Property
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Via Chartmill
News headline image
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
Via ACCESS Newswire
News headline image
Should You Buy Moderna Before Feb. 13? ↗
The biotech has momentum as its quarterly report approaches. 
Via The Motley Fool
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a... 
Via Finterra
Topics ETFs Economy Initial Public Offering
News headline image
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Tom Gardner's 2026 Outlook: Volatility, Government Scrutiny, and Two AI-Adjacent Stocks ↗
Tom Gardner outlines two selective AI opportunities and a disciplined portfolio framework for the next three to five years. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.
From Defiance ETFs
Via GlobeNewswire
Gapping S&P500 stocks in Monday's session ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
Dr. David Berman to Join Moderna as Chief Development Officer
Via ACCESS Newswire
News headline image
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
Via ACCESS Newswire
News headline image
3 ETFs Catapulting Beyond the S&P to Start the Year ↗
Via MarketBeat
Topics ETFs Stocks
News headline image
This Stock Is Already Up 58% This Year. Is It a Buy? ↗
This forgotten pandemic stock hasn't said its last word. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.